上尿路尿路上皮癌患者林奇综合征的通用即时检测
该研究对115例无林奇综合征病史的上尿路尿路上皮癌患者进行通用即时筛查,采用AMS I/II标准、错配修复蛋白免疫组化及微卫星不稳定性检测。16例(13.9%)筛查阳性,其中6例确诊林奇综合征(5.2%)。结论认为上尿路尿路上皮癌中林奇综合征确诊率高达5.2%,具有重要临床意义。
要点
- 115例上尿路尿路上皮癌患者中16例(13.9%)筛查阳性,6例(5.2%)确诊林奇综合征。
- 筛查方法包括AMS II标准(7.0%)、错配修复蛋白缺失(11.3%)及高度微卫星不稳定性(6.0%)。
- 已知林奇综合征的7例患者均满足AMS II标准且至少一种错配修复蛋白缺失。
核心结论
- 上尿路尿路上皮癌患者中13.9%为潜在林奇综合征,5.2%为确诊林奇综合征,代表泌尿系统肿瘤中未确诊遗传病最高比率之一。
研究设计与样本
- 前瞻性通用筛查研究,纳入2013年1月至2016年7月随访期间115例 consecutive 无林奇综合征病史的上尿路尿路上皮癌患者,以已知林奇综合征患者作为阳性对照。
主要发现
- 115例患者中16例(13.9%)筛查阳性,其中7.0%满足AMS II标准,11.3%存在至少一种错配修复蛋白缺失,6.0%具有高度微卫星不稳定性。
- 16例筛查阳性患者均转诊进行胚系检测,9例完成遗传分析与咨询,6例确诊林奇综合征。
- 已知林奇综合征的7例上尿路尿路上皮癌患者均满足AMS II标准且至少一种错配修复蛋白缺失,6例中5例具有高度微卫星不稳定性。
关键数值与推荐
- 筛查阳性标准:满足AMS I/II标准、微卫星不稳定性或免疫组化异常。
- 筛查阳性率13.9%(16/115),确诊林奇综合征率5.2%(6/115)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with Lynch syndrome are at risk for upper tract urothelial carcinoma. We sought to identify the incidence and most reliable means of point of care screening for Lynch syndrome in patients with upper tract urothelial carcinoma. MATERIALS AND METHODS: A total of 115 consecutive patients with upper tract urothelial carcinoma without a history of Lynch syndrome were universally screened during followup from January 2013 through July 2016. We evaluated patient and family history using AMS (Amsterdam criteria) I and II, and tumor immunohistochemistry for mismatch repair proteins and microsatellite instability. Patients who were positive for AMS I/II, microsatellite instability or immunohistochemistry were classified as potentially having Lynch syndrome and referred for clinical genetic analysis and counseling. Patients with known Lynch syndrome served as positive controls. RESULTS: Of the 115 patients 16 (13.9%) screened positive for potential Lynch syndrome. Of these patients 7.0% met AMS II criteria, 11.3% had loss of at least 1 mismatch repair protein and 6.0% had high microsatellite instability. All 16 patients were referred for germline testing, 9 completed genetic analysis and counseling, and 6 were confirmed to have Lynch syndrome. All 7 patients with upper tract urothelial carcinoma who had a known history of Lynch syndrome were positive for AMS II criteria and at least a single mismatch repair protein loss while 5 of 6 had high microsatellite instability. CONCLUSIONS: We identified 13.9% of upper tract urothelial carcinoma cases as potential Lynch syndrome and 5.2% as confirmed Lynch syndrome at the point of care. These findings have important implications for universal screening of upper tract urothelial carcinoma, representing one of the highest rates of undiagnosed genetic disease in a urological cancer.
引用
- Metcalfe MJ, Petros FG, Rao P, et al. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. J Urol. 2017. PMID: 28797715. doi:10.1016/j.juro.2017.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。